New Delhi: The Union Health Ministry, on Tuesday (January 17), refuted the media reports claiming admission of ‘multiple side-effects of COVID-19 vaccines’ by Indian Council of...
New Delhi: The Drugs Controller General of India (DCGI) has approved the market authorisation of Serum Institute of India’s (SII) COVID-19 vaccine Covovax as a heterologous...
Covovax is actually the best booster because it works very well against Omicron, more than Covishield, said Serum Institute of India's CEO Adar Poonawalla
The vaccine will be available in private hospitals and will be included in the COVID-19 vaccination programs from December 23. The CoWIN platform will also be...
People previously infected with the SARS-CoV-2 virus still benefit from vaccination against COVID-19, gaining 60 per cent to 94 per cent protection against reinfection, according to...
Covishield was produced at the SII's Pune facility with a master seed from Oxford University and AstraZeneca
The Central Government is committed to accelerating the pace and expanding the scope of COVID-19 vaccination throughout the country. The nationwide COVID-19 vaccination started on January...
Earlier, Bharat Biotech had announced the approval for its iNCOVACC (BBV154), the world’s first intranasal COVID-19 vaccine, from the DCGI for restricted use in emergencies for...
The study said that people who received at least two doses of the COVID-19 vaccination compared to those who received none experienced 8 of the 10...